Marwah Medicine

INICET, Medical, Medicine, Medicine classes, NExT, NExT Exam

FDA Approves First Oral Drug for Dermatomyositis

Brepocitinib (Lisraya) Explained: Mechanism, VALOR Trial, Dose, Safety & Exam Pearls By Dr Deepak Marwah  |  Marwah Medicine A major change has arrived in dermatomyositis treatment. On August 27, 2026, the US FDA approved brepocitinib (Lisraya) tablets for adults with dermatomyositis, making it the first FDA-approved oral treatment specifically indicated for adult dermatomyositis. HIGH-YIELD ONE-LINER Brepocitinib = oral selective TYK2-JAK1 inhibitor → adult dermatomyositis. For medical students, that one line may be enough to answer a future NEET-PG, INI-CET or FMGE update question. For clinicians, however, the story is more interesting: the Phase 3 VALOR trial showed meaningful improvement in overall dermatomyositis activity, skin disease, physical function and glucocorticoid tapering with the 30-mg dose. Why this approval matters Dermatomyositis is a systemic autoimmune inflammatory myopathy. The classic teaching focuses on proximal muscle weakness, heliotrope rash and Gottron papules, but clinically the disease may involve skin, muscle, joints, lungs and other organs. Treatment has traditionally relied heavily on glucocorticoids and other immunomodulatory therapies, many used off-label. A specifically approved oral targeted therapy therefore represents an important change in the treatment landscape. What exactly is brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1. These kinases participate in intracellular cytokine signaling pathways involved in immune activation and inflammation. Think of the pathway as: Cytokine signal → JAK/TYK signaling → inflammatory gene signaling → immune-mediated tissue injury. By inhibiting TYK2 and JAK1, brepocitinib modifies several inflammatory signaling pathways implicated in dermatomyositis. The study behind the approval: VALOR The pivotal evidence came from the Phase 3 VALOR trial, a double-blind randomized placebo-controlled study involving 241 adults with dermatomyositis. Participants received brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo for 52 weeks. Background standard therapies were continued and glucocorticoids were tapered. What did the trial show? Group Mean Total Improvement Score at Week 52 Brepocitinib 30 mg 46.5 Brepocitinib 15 mg 37.5 Placebo 31.2 The 30-mg dose was significantly superior to placebo for the primary endpoint. Importantly, brepocitinib 30 mg was also superior across all nine key secondary endpoints, including skin disease activity, systemic glucocorticoid tapering and functional disability. Improvements in some outcomes were observed as early as week 4. It was not just about muscle enzymes One of the clinically attractive aspects of the VALOR results is that benefit was not restricted to a laboratory value. Dermatomyositis can produce persistent and troublesome cutaneous disease even when muscle manifestations are less dramatic. The 30-mg dose demonstrated improvement across clinically relevant domains including skin activity and physical function. The steroid-sparing angle Long-term glucocorticoid exposure carries substantial toxicity, including diabetes, osteoporosis, infection risk, cataracts, hypertension and weight gain. In VALOR, improvement with brepocitinib 30 mg was accompanied by greater glucocorticoid tapering. This makes the result clinically more meaningful than a change in a single disease marker. Does this replace steroids? No. The approval should not be interpreted as meaning that every newly diagnosed patient can simply replace conventional therapy with one tablet. Dermatomyositis is heterogeneous. Treatment decisions still depend on the severity and pattern of muscle disease, dysphagia, respiratory involvement, interstitial lung disease, skin disease, autoantibody profile, malignancy evaluation, previous treatment response and patient-specific risks. Also remember an important trial detail: standard therapies were continued while glucocorticoids were tapered. Brepocitinib adds a new targeted option; it does not erase the need for individualized specialist management. Dose: the number worth remembering The FDA-approved Lisraya tablet contains brepocitinib 30 mg, administered orally once daily for adults with dermatomyositis. Safety: oral does not mean casual Brepocitinib is a potent immunomodulatory therapy. In VALOR, serious infections occurred more frequently with brepocitinib 30 mg than with placebo (10% versus 1%). The FDA prescribing information contains important warnings and precautions, including serious infections, malignancy, major adverse cardiovascular events and thrombosis. Common adverse reactions reported in the FDA medication information include upper respiratory tract infections, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, falls, influenza and acne. Clinical message: “Oral” should never be confused with “low-risk.” Appropriate patient selection, screening and monitoring remain essential. What should medical students remember? Drug: Brepocitinib Trade name: Lisraya Route: Oral, once daily Dose: 30 mg once daily Mechanism: Selective TYK2-JAK1 inhibitor Indication: Dermatomyositis in adults FDA approval: August 27, 2026 Key trial: VALOR Potential exam question A patient with dermatomyositis is started on a newly FDA-approved oral therapy that selectively inhibits TYK2 and JAK1. Which drug is most likely being prescribed? Answer: Brepocitinib (Lisraya). The bigger lesson: targeted therapy is entering myositis For years, dermatomyositis was taught through its memorable clinical signs: heliotrope rash, Gottron papules and proximal muscle weakness. Those remain fundamental. But modern medicine increasingly asks a second question: which molecular pathways are driving the disease, and can those pathways be targeted? Brepocitinib represents that transition from broad immunosuppression toward more targeted immune modulation. Its ultimate place in treatment algorithms will continue to evolve with real-world experience, longer-term safety data, accessibility and cost. But the 2026 approval itself is already an important milestone in dermatomyositis therapy. Frequently Asked Questions What is the new oral drug for dermatomyositis? Brepocitinib, marketed as Lisraya, was FDA-approved in August 2026 for the treatment of dermatomyositis in adults. What is the mechanism of brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1, modifying cytokine signaling involved in inflammatory and autoimmune pathways. What is the dose of brepocitinib for dermatomyositis? The FDA-approved Lisraya dose is 30 mg orally once daily. Is brepocitinib a JAK inhibitor? Yes. Brepocitinib selectively inhibits TYK2 and JAK1. Is brepocitinib better than steroids for dermatomyositis? The treatments should not be reduced to a simple either-or comparison. In VALOR, background standard therapies were continued while glucocorticoids were tapered. The 30-mg brepocitinib group showed clinical benefit and greater glucocorticoid tapering. What is the most important safety concern? Serious infection risk is important. The FDA label also contains warnings and precautions regarding malignancy, major adverse cardiovascular events and thrombosis. What should NEET-PG and INI-CET students remember? Brepocitinib → oral TYK2-JAK1 inhibitor → adult dermatomyositis. Remember the 30-mg once-daily dose […]

Medical, Medicine, Medicine classes

A PCSK9 Inhibitor in a Tablet? Meet Enlicitide, the New Oral Cholesterol Drug

For years, there was an easy examination question: “What is the major disadvantage of PCSK9 inhibitors?” One obvious answer was: they are injectable. Not anymore. On July 17, 2026, the US FDA approved enlicitide, marketed as Lipfendra, making it the first FDA-approved oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). In the pivotal clinical program, oral enlicitide produced roughly 56–59% placebo-adjusted reductions in LDL cholesterol at 24 weeks. For a once-daily tablet, that number deserves attention. HIGH-YIELD ONE-LINER: Enlicitide = first oral PCSK9 inhibitor that lowers LDL-C by 65%. WOW!   First, revise PCSK9 in 30 seconds The liver removes circulating LDL cholesterol using LDL receptors. After an LDL particle binds its receptor, the complex is internalized into the hepatocyte. Normally, the LDL receptor can be recycled back to the hepatocyte surface and used again. PCSK9 binds LDL receptors and promotes their degradation. ↑ PCSK9 → ↓ LDL receptors → ↑ circulating LDL-C Block PCSK9 → ↑ recycled LDL receptors → ↑ LDL clearance → ↓ LDL-C That is why PCSK9 became such an attractive therapeutic target. But didn’t we already have PCSK9 drugs? Yes. Alirocumab and evolocumab are monoclonal antibodies targeting PCSK9 and are administered subcutaneously. Inclisiran approaches the pathway differently: it uses small-interfering RNA to reduce hepatic PCSK9 synthesis and is also injectable. The conceptual change with enlicitide is simple: PCSK9 lowering has entered the tablet era. How effective is enlicitide? The FDA approval was supported by randomized, double-blind, placebo-controlled studies in adults with hypercholesterolemia receiving background lipid-lowering therapy. The primary efficacy measure was percentage change in LDL-C at week 24. Population Approx. baseline LDL-C Placebo-adjusted LDL-C reduction at week 24 ASCVD/high cardiovascular risk 96 mg/dL ~56% Heterozygous familial hypercholesterolemia 119 mg/dL ~59% These are substantial LDL reductions and explain why an oral PCSK9 inhibitor has generated considerable clinical interest. The CORALreef story In the Phase 3 CORALreef Lipids study, nearly all participants were receiving statins. At week 24, LDL-C fell markedly with enlicitide while remaining essentially unchanged in the placebo group. Enlicitide also reduced non-HDL cholesterol, apolipoprotein B and lipoprotein(a). The key teaching point is that enlicitide was not developed simply as a replacement for statins in untreated patients. It is a potent additional LDL-lowering option for patients who remain above their recommended LDL level despite background therapy. How does it compare with other oral non-statin drugs? The CORALreef AddOn study provided a useful short-term comparison in statin-treated patients whose LDL remained above target. At day 56, the reported mean LDL-C reductions were approximately: Treatment Approx. LDL-C reduction Enlicitide 65% Ezetimibe 28% Bempedoic acid 6% Bempedoic acid + ezetimibe 37% These are lipid-efficacy comparisons over a relatively short period, not comparisons of cardiovascular outcomes. They nevertheless illustrate the potency of oral PCSK9 inhibition. Does enlicitide replace statins? No. Statins remain foundational therapy for LDL lowering and cardiovascular risk reduction in appropriate patients. The more useful clinical question is what to add when statin therapy does not lower LDL sufficiently, or when treatment needs to be individualized because of tolerance, risk, access or other clinical considerations. Depending on the patient, non-statin options may include ezetimibe, bempedoic acid and PCSK9-directed therapies. Why 2026 is a big year for LDL management The 2026 ACC/AHA dyslipidemia guideline also updated the way clinicians think about lipid management, including explicit LDL-C goals and use of PREVENT-ASCVD equations for primary-prevention risk assessment. Borderline/intermediate-risk primary prevention: LDL-C <100 mg/dL High-risk primary prevention: LDL-C <70 mg/dL Very-high-risk ASCVD: LDL-C <55 mg/dL Very-high-risk ASCVD → think LDL-C <55 mg/dL. The guideline also emphasizes measuring lipoprotein(a), or Lp(a), at least once in adulthood. Together, the new guideline and the arrival of an oral PCSK9 inhibitor make lipid management one of the most important cardiovascular update areas of 2026. Is enlicitide safe? Across the major studies, overall adverse-event rates were broadly comparable between enlicitide and placebo. Reported adverse reactions included symptoms such as diarrhea and dizziness in relevant study populations. As with any newly introduced therapy, prescribing should follow the approved product information and the patient’s individual clinical context. A new drug should not be prescribed merely because an LDL value is elevated. Absolute cardiovascular risk, LDL level, prior therapy, tolerability, comorbidities and current guideline recommendations remain central. The limitation every doctor should understand Enlicitide has demonstrated powerful LDL lowering. But lowering LDL in a lipid-efficacy trial and directly demonstrating fewer myocardial infarctions, strokes or cardiovascular deaths are not identical endpoints. The pivotal studies established strong lipid effects. Long-term cardiovascular outcome evidence will be important in defining the drug’s ultimate place in preventive cardiology. The scientifically correct message today is: enlicitide markedly lowers LDL; the magnitude of its eventual cardiovascular-outcome benefit should be judged from dedicated outcome evidence. NEET-PG / INI-CET / FMGE Exam Box A patient with hypercholesterolemia is prescribed the first FDA-approved oral inhibitor of PCSK9. Which drug has been prescribed? Inclisiran Evolocumab Enlicitide Alirocumab Answer: C. Enlicitide Make these associations automatic: Enlicitide → oral PCSK9 inhibitor Evolocumab / Alirocumab → monoclonal antibodies against PCSK9 Inclisiran → siRNA → decreases hepatic PCSK9 synthesis The bigger story This is not simply another cholesterol tablet. For years, PCSK9-directed treatment meant an injection. Enlicitide changes that practical assumption. Whether oral administration substantially expands PCSK9 use will depend on cardiovascular outcome evidence, long-term safety, cost, availability and real-world adherence. But one fact has already changed: PCSK9 inhibition is no longer an injection-only strategy. And that is precisely the kind of update that separates current clinical medicine from an outdated textbook. Keep Hammering. Frequently Asked Questions What is the first oral PCSK9 inhibitor? Enlicitide (Lipfendra) is the first FDA-approved oral PCSK9 inhibitor. It was approved in July 2026 for adults with hypercholesterolemia, including HeFH. How much does enlicitide lower LDL cholesterol? Pivotal studies reported placebo-adjusted LDL-C reductions of roughly 56% at week 24 in an ASCVD/high-risk population and roughly 59% in patients with HeFH. Is enlicitide an injection? No. Enlicitide is an oral once-daily therapy, distinguishing it from previously approved injectable PCSK9-directed treatments. […]

Medicine, NEET PG

Marburg virus: Outbreak in Africa in Feb 2023

Family Filovirus Type RNA virus First identified 1967 Reservoir host  African fruit bat Rousettus aegyptiacus Countries that have reported outbreaks historically Human to human spread 1.      Blood or body fluids (urine, saliva, sweat, feces, vomit, breast milk, amniotic fluid, and semen) of a person who is sick with or died from Marburg virus disease. 2.      Objects contaminated with body fluids from a person who is sick with or has died from Marburg virus disease (such as clothes, bedding, needles, and medical equipment). 3.      Semen (persists in testicles and eye) Clinical features Incubation period: 2-21 days Day 1: Fever chills and myalgia Day 5: Rash on trunk. Abdominal pain and diarrhea Old Symptoms worsen with appearance of jaundice, pancreatitis, severe weight loss, delirium, shock, liver failure, coagulopathy and MODS.   #NEETPG #MEDICINE #FMGCOACHING

Medicine, NEET PG

RAPID REVISION MEDPATH

2-Minute Read #NEETPG #INICET #FMG #Titin #ninjastarnucleus #cardiomyopathy The following slides give you a quick ready recknoner for quick revision of histopathological slides of hypertrhophic cardiomyopathy versus dilated cardiomyopathy vs restrictive cardiomyopathy vs arrythmogenic RV dysplasia. ECG findings in various cardiomyopathies HCM SV1 and RV5/6 > 35 mm Hg due to LVH RCM Low voltage ECG due to fibrosis DCM ECG shows non-specific ST segment and T wave changes ARVD Epsilon wave  

Medicine, NEET PG

Ninja Star Nucleus in Dilated cardiomyopathy

2-Minute Read #NEETPG #INICET #Ninjastar #titinmutation TTN gene encodes for Titin which is the largest human protein composed of 33K amino acids. It is the third most abundant striated muscle protein. TTN mutations leads to dilated cardiomyopathy. Clinical features of Dilated cardiomyopathy are identical to forward and backward failure features of CHF leading to pulmonary edema and pedal edema. Key points that help you in 30 seconds whether examiner is asking about Dilated cardiomyopathy leading to CHF findings are as follows: Pick up points in MCQ:   Pulse Dicrotic pulse Murmurs Functional Murmurs of chronic Mitral and tricuspid regurgitation Pansystolic murmur of left and right can be differentiated as right sided murmurs will increase on inspiration. JVP Elevated JVP that does not fall with inspiration called Kussmual sign Per Abdomen Hepatomegaly with Ascites Echocardiography  Gross dilatation of all chambers of heart with reduced wall thickness. Coronary angiography Normal as ischemia must be ruled out before commenting on cardiomyopathy Histopathology Hyperchromatic highly distorted Ninja star like nuclei If seen in > 5% of myocytes it is highly suggestive of titin truncating mutation Do not confuse its nucleus with box car nuclei of hypertrophied muscles due to untreated hypertension.  

Medicine, NEET PG

How to read Harrison in last month before NEET SS. AIR Rank 37 Dr Subrata explains

2-Minute Read #NEETSS #PREPLADDER #marwahmedicine Here is thefinal month strategy of a young dashing Dr Subhabrata who secured AIR 37 in NEET SS 2023. He says that there was no time for video lectures in that last month. The slight delay of exam by 20 days was a blessing in disguise as it gives me extra days to cover those topics that I was initially plan to leave and go. I took screen shots of all Harrison tables and used to revise them daily whenever I got timex whether before or during duty hours. I developed visual memory of each table by going through these tables which was sometimes simple blank staring into the screen even if it was in the wards. In simple words I was so attached to the theory and flow charts that performing in wards was literally muscle memory I used to wake up one hour earlier than duty time and used to hit books or app Q bank immediately on coming back from duty instead of relaxing and planning to study later. After duty you are operating on adrenaline and soon the effect will fade off and muscles will demand rest. Use that time before the adrenaline of duty wears off. Use a highlighter and make notes in separate notebook. Writing down will help you remember more though you may feel lazy. Rather you will be surprised that you will not have to read that topic again and again as when you note down data, it gets more organized and more understandable. I used to do only Q bank and test series during last 1-2 months of preparation. Imagine you are in examination hall while doing each MCQ. It helps you fine tune your senses. Being mentally dull while lying partially reclining in bed is a big no. Don’t do MCQ while lounging and lying down. It will dull your reflexes. Using supplemental resources, Harrison is not the only resource available. Use review articles and online resources. Join limited WhatsApp groups for any updates that are coming for management but be very selective about those groups. Achieving Daily targets is more important than making grand plans and failing. Don’t neglect environmental medicine and poisoning.    

Medicine

Once-Weekly Insulin Approved in India: A New Era in Diabetes Management

For the first time, once-weekly basal insulin has been approved in India, marking one of the biggest advances in insulin therapy in decades. The approved molecule is Insulin Icodec, a long-acting basal insulin designed to provide 7-day glucose control with a single weekly injection. What is Insulin Icodec? Insulin Icodec is an ultra-long-acting basal insulin analogue developed for adults with diabetes requiring basal insulin therapy. Key Point 1 injection every week Replaces 7 daily basal insulin injections   How Does It Last for 7 Days? Insulin Icodec has been engineered to: Bind strongly to albumin Be released slowly into circulation Maintain stable insulin levels throughout the week This provides a continuous basal insulin effect without major peaks.   Advantages Over Daily Basal Insulin   Only 1 injection per week Better treatment adherence Reduced injection fatigue Similar HbA1c reduction compared with daily basal insulin in clinical trials May improve patient satisfaction and quality of life   Which Patients May Benefit? Once-weekly insulin may be considered for: Type 2 diabetes requiring basal insulin Patients reluctant to start insulin because of daily injections Individuals with poor adherence to daily basal insulin Clinical use should always follow physician guidance and approved prescribing recommendations. Is It for Type 1 Diabetes? Current approval and clinical use primarily focus on adults with Type 2 diabetes requiring basal insulin. Its role in Type 1 diabetes remains more limited and depends on regulatory approvals and clinical guidance. Important Clinical Points It is basal insulin, not mealtime insulin. Rapid-acting insulin is still required when indicated. Weekly dosing requires careful initiation and dose titration. Missing one dose can have a larger impact than missing a single daily basal dose. NEET PG Pearls Feature High-Yield Fact Drug Insulin Icodec Frequency Once weekly Type Ultra-long-acting basal insulin Major Benefit Improves adherence by reducing injections Replaces Daily basal insulin Not Used As Prandial (mealtime) insulin   Memory Trick ICODEC = I COME Once Every Week Remember: Icodec is Once Weekly Basal Insulin   NEET PG/ INICET / FMGE MCQ A newly approved basal insulin in India provides glycemic control with a single injection every week. Which insulin is being described? Insulin Lispro Insulin Glargine Insulin Icodec Insulin Aspart Answer: C. Insulin Icodec Explanation: Insulin Icodec is an ultra-long-acting basal insulin analogue that maintains glucose control for one week, significantly reducing the number of injections required compared with conventional daily basal insulin. Dr Marwah NEET PG Educator for 2 decades generating good, ethical doctors   Links of must watch videos of this channel https://www.youtube.com/watch?v=5reXtUFW-Y0 https://www.youtube.com/watch?v=K-YNyzLENEE https://www.youtube.com/live/houmdnMAmdI

Medicine, NEET PG, NExT, NExT Exam

Atrial Fibrillation

2min read #NEETPG #INICET #FMG #FMGMCIEXAM #MEDICINEVIDEOLECTURES #RAPIDREVISIONMEDICINE #NEETSS Notice the irregular RR interval with absence of P waves which is characteristic feature of Atrial fibrillation. You can differentiate from multifocal atrial tachycardia which has >3 morphology of P waves present. Common causes of Atrial fibrillation: ABCD- OT Age: 60 years old Blood Pressure high /Hypertension Cardiac conditions: Coronary artery disease, Cardiac valve disorders, congenital heart defects COPD Diabetes: Individuals with diabetes have an elevated risk of developing AFib. Dilated Cardiomyopathy due to long term alcohol intake leading to Holiday heart syndrome Obstructive sleep apnea Thyroid disease   Clinical features of Atrial fibrillation Irregular Heartbeat: The hallmark of AFib is an irregular and often rapid heartbeat. The pulse may feel chaotic and irregular when palpating the wrist. Palpitations: Some individuals with AFib may feel palpitations, which are sensations of rapid, fluttering, or pounding heartbeats. Fatigue: AFib can lead to reduced cardiac output, causing fatigue and a sense of low energy. Shortness of Breath: Pooling of blood in lungs due to Inability of the heart to pump blood effectively can result in shortness of breath, especially during physical activity. Dizziness or Lightheadedness: Inadequate blood flow to the brain due to irregular heartbeats can cause dizziness or lightheadedness. Chest Pain or Discomfort While chest pain is not as common in AFib as it is in some other heart conditions, some individuals may experience chest discomfort. Syncope (Fainting): In severe cases, AFib can lead to a drop in blood pressure, causing fainting or loss of consciousness. Increased Risk of Stroke: A.Fib is associated with an increased risk of blood clot formation in the atria, which can travel to the brain and cause a stroke. Some individuals may not have noticeable symptoms but are at risk of stroke. Creating a mnemonic can be a helpful memory aid for remembering the treatment of atrial fibrillation. Here’s a mnemonic for the general principles of AFib treatment: Management of Atrial fibrillation: RACE (Remembering “RACE” can help you recall the key components of atrial fibrillation treatment) Rate Control: Use medications to control the heart rate, preventing it from becoming too fast. Common medications include beta-blockers, calcium channel blockers, and sometimes digoxin. Anticoagulation: Reduce the risk of blood clots and stroke by prescribing anticoagulant medications. Common options include warfarin, dabigatran, rivaroxaban, apixaban. For Rheumatic heart disease leading to MS and then atrial fibrillation warfarin is preferred. For Non valvular atrial fibrillation, NOAC are preferred. Chemical Cardioversion: Convert the irregular rhythm back to a normal sinus rhythm. This can be achieved through electrical cardioversion (shocks) or pharmacological cardioversion using medications like amiodarone. Electrical cardioversion: Synchronized DC shock Evaluate and Treat Underlying Causes: Identify and manage any underlying conditions contributing to atrial fibrillation, such as hypertension, heart valve disorders, or thyroid problems

Medicine, NEET PG, NExT, NExT Exam

Broken heart syndrome/ Takotsubo Cardiomyopathy/ Apical Ballooning syndrome

2 min read #NEETPG #INICET #FMGE #DRMARWAHLIVE Broken heart syndrome, also known as stress-induced cardiomyopathy or Takotsubo cardiomyopathy, is a condition where intense emotional or physical stress can cause sudden and severe heart muscle weakness or dysfunction. This condition can mimic a heart attack with symptoms such as chest pain, shortness of breath, and irregular heartbeats, but it’s not caused by blocked arteries typical of a heart attack. Happy Valentine day and be selective about who you date while you keep reading Pathophysiology: It is believed that a surge of stress hormones, such as adrenaline, may temporarily damage the heart muscle, leading to the characteristic symptoms.   Here are some key points about broken heart syndrome: Triggering Factors: Broken heart syndrome can be triggered by various emotional or physical stressors, such as the death of a loved one, a breakup, financial loss, a serious medical diagnosis, or even a surprise party. Symptoms: The symptoms of broken heart syndrome can resemble those of a Myocardial infarction and may include chest pain, shortness of breath, arrhythmias, and in some cases, fainting. Diagnostic Work up: ECG will show ST Elevation Troponin I will be Elevated Echo will show Apical Ballooning Image Coronary angiography will be normal and not show any coronary artery occlusion by any thrombus as it does in STEMI. Therefore, it is a diagnosis of exclusion. Always Rule out Myocarditis and Pheochromocytoma Treatment: Treatment for broken heart syndrome usually involves supportive care to stabilize the patient and manage features of Acute CHF. Intra-aortic balloon pump is preferred over inotropes in cardiogenic shock for broken heart syndrome. Other medications to reduce the workload on the heart, such as beta-blockers, ACE inhibitors are used along with diuretics to relieve pulmonary edema. Most patients recover within a few weeks to months with appropriate medical management. Prognosis: The prognosis for broken heart syndrome is generally favorable, with most patients recovering completely without long-term complications. However, in some cases, there can be complications such as heart failure, arrhythmias, or in rare cases, death.

Medicine, Medicine classes, NEET PG, NExT, NExT Exam

HYPERSENSITIVITY PNEUMONITIS

#NEETPG #INICET #FMG #MCISCREENING #MARWAHMEDICINE #PREPLADDERMEDICINE Here is a Quick mnemonic to remember the features of Hypersensitivity pneumonitis is: FARMER’S LUNG 4 F – Fever and Breathing problems A – Acute onset on exposure to grain, Moldy hay and Silage which harbor Thermophilic Actinomycetes R – Respiratory symptoms (cough, dyspnea and Clubbing is seen too M – Malaise starting within 4 to 8 hours of antigenic exposure E – Elevated erythrocyte sedimentation rate and BAL shows lymphocytosis R – Radiographic findings (ground-glass opacities, reticulonodular infiltrates) S – Symptoms improve with removal from exposure L – Lymphocytic alveolitis U – Uncommon but can progress to chronic disease N – Noncaseating granulomas G – Granulomatous inflammation and Diagnosis is based on Clinical prediction rule 4- Type 4 hypersensitivity reaction This mnemonic can help you recall the key features associated with Hypersensitivity pneumonitis.

Scroll to Top